Aviva Singapore to cover COVID-19 vaccine side effects

This is included for clients' Integrated Shield Plan, MyShield and group plans.

Aviva Singapore has extended its health insurance coverage to include expenses arising from allergic reactions to the COVID-19 vaccine at no additional premium.

This coverage is included for their Integrated Shield Plan, MyShield, as well as group health insurance plans. The Health Sciences Authority must authorise the vaccine, and the individual must be medically eligible to receive it.

“We made this decision to assure Aviva’s policyholders who may have concerns about medical expenses should they encounter side effects from the vaccine. As an insurer, it is our responsibility to act quickly and meet the evolving needs and apprehensions of individuals, thus ensuring the country’s national vaccination effort can run smoothly,” said Aviva Singapore director of product & marketing Daniel Lum.

Join Singapore Business Review community
Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Top News

September surge masks looming export slowdown to 6% in 2027
Maybank raised its 2026 forecast to 27% from 18% in the same report.Non-oil domestic exports (NODX) growth could slow to 6% in 2027 as supply chain pressures and higher financing costs weigh on shipment momentum, Maybank Research Pte Ltd said.
Economy